-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers' spending habits, particularly in the food industry.
Novo Nordisk A/S's (NYSE:NVO) Wegvoy (semaglutide) and Eli Lilly And Co's (NYSE:LLY) Zepbound (tirzepatide) have amassed stupendous popularity as miracle weight loss drugs, as makers struggle to cope up with the demand.
Related: Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025.
The survey, involving 300 individuals currently on GLP-1 medication, indicates a significant decrease in appetite among users, leading to reduced spending on food in restaurants and grocery stores.
The survey findings suggest that most GLP-1 users are cutting back on dining out and ordering takeout, with 63% reporting reduced spending on restaurant meals.
Similarly, 61% mentioned spending less on deliveries or takeout, highlighting a shift in consumer behavior towards more frugal eating habits.
Although the increased demand for GLP-1 drugs poses potential challenges for food and beverage companies, CNBC, citing Morgan Stanley analysts, highlights that certain sectors are better positioned to navigate this shift.
Healthier fast-casual restaurants and coffee chains like Cava Group Inc (NYSE:CAVA), Chipotle Mexican Grill Inc (NYSE:CMG), Sweetgreen Inc (NYSE:SG), and Starbucks Corporation (NASDAQ:SBUX) are expected to fare better than traditional fast-food establishments.
On the other hand, packaged food companies like The Hershey Company (NYSE:HSY) may face higher risks due to their focus on indulgent snacks.
However, according to the survey, companies offering healthier food options are likely to benefit from the rise in GLP-1 usage.
In addition to impacting food consumption, the survey also suggests a potential influence of GLP-1 drugs on addictive behaviors such as smoking.
A notable decline in both traditional cigarette and e-cigarette use was observed among respondents after starting GLP-1 treatment.
While the survey provides valuable insights into the changing consumption patterns associated with GLP-1 medications, Morgan Stanley remains cautious about drawing definitive conclusions regarding their impact on addictive behaviors.
Ongoing medical research in this area will be crucial in understanding the full extent of GLP-1 effects.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Vidmir Rais via Pixabay
A recent survey conducted by Morgan Stanley reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers' spending habits, particularly in the food industry.
摩根士丹利最近进行的一项调查显示,在减肥和糖尿病方面广受欢迎的 GLP-1 药物的使用正在影响消费者的消费习惯,尤其是在食品行业。
Novo Nordisk A/S's (NYSE:NVO) Wegvoy (semaglutide) and Eli Lilly And Co's (NYSE:LLY) Zepbound (tirzepatide) have amassed stupendous popularity as miracle weight loss drugs, as makers struggle to cope up with the demand.
由于制造商难以满足需求,诺和诺德A/S(纽约证券交易所代码:NVO)的Wegvoy(semaglutide)和礼来公司(纽约证券交易所代码:LLY)的Zepbound(tirzepatide)作为奇迹减肥药物广受欢迎。
Related: Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025.
相关:患者发现减肥药Zepbound可以改变游戏规则,但制造商认为生产将推迟到2025年。
The survey, involving 300 individuals currently on GLP-1 medication, indicates a significant decrease in appetite among users, leading to reduced spending on food in restaurants and grocery stores.
该调查涉及目前正在服用 GLP-1 药物的 300 人,表明使用者的食欲显著下降,导致餐馆和杂货店的食物支出减少。
The survey findings suggest that most GLP-1 users are cutting back on dining out and ordering takeout, with 63% reporting reduced spending on restaurant meals.
调查结果表明,大多数 GLP-1 用户都在减少外出就餐和订购外卖的时间,63% 的用户表示减少了餐厅用餐的支出。
Similarly, 61% mentioned spending less on deliveries or takeout, highlighting a shift in consumer behavior towards more frugal eating habits.
同样,61%的人表示减少了送货或外卖支出,这凸显了消费者行为向更节俭的饮食习惯的转变。
Although the increased demand for GLP-1 drugs poses potential challenges for food and beverage companies, CNBC, citing Morgan Stanley analysts, highlights that certain sectors are better positioned to navigate this shift.
尽管对 GLP-1 药物需求的增加给食品和饮料公司带来了潜在的挑战,但CNBC援引摩根士丹利分析师的话强调,某些行业更有能力应对这一转变。
Healthier fast-casual restaurants and coffee chains like Cava Group Inc (NYSE:CAVA), Chipotle Mexican Grill Inc (NYSE:CMG), Sweetgreen Inc (NYSE:SG), and Starbucks Corporation (NASDAQ:SBUX) are expected to fare better than traditional fast-food establishments.
预计卡瓦集团公司(纽约证券交易所代码:CAVA)、Chipotle Mexico Grill Inc(纽约证券交易所代码:CMG)、Sweetgreen Inc(纽约证券交易所代码:SG)和星巴克公司(纳斯达克股票代码:SBUX)等更健康的快餐店和咖啡连锁店的表现将好于传统的快餐店。
On the other hand, packaged food companies like The Hershey Company (NYSE:HSY) may face higher risks due to their focus on indulgent snacks.
另一方面,像好时公司(纽约证券交易所代码:HSY)这样的包装食品公司由于专注于放纵性零食而可能面临更高的风险。
However, according to the survey, companies offering healthier food options are likely to benefit from the rise in GLP-1 usage.
但是,根据调查,提供更健康食品选择的公司可能会从 GLP-1 使用量的增加中受益。
In addition to impacting food consumption, the survey also suggests a potential influence of GLP-1 drugs on addictive behaviors such as smoking.
除了影响食物消费外,该调查还表明,GLP-1 药物可能对吸烟等成瘾行为产生影响。
A notable decline in both traditional cigarette and e-cigarette use was observed among respondents after starting GLP-1 treatment.
开始 GLP-1 治疗后,受访者观察到传统香烟和电子烟的使用量均显著下降。
While the survey provides valuable insights into the changing consumption patterns associated with GLP-1 medications, Morgan Stanley remains cautious about drawing definitive conclusions regarding their impact on addictive behaviors.
尽管该调查为与 GLP-1 药物相关的不断变化的消费模式提供了宝贵的见解,但摩根士丹利对得出有关其对成瘾行为的影响的明确结论仍持谨慎态度。
Ongoing medical research in this area will be crucial in understanding the full extent of GLP-1 effects.
该领域正在进行的医学研究对于了解 GLP-1 影响的全部范围至关重要。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明: 该内容部分是在人工智能工具的帮助下制作的,并由Benzinga编辑审阅和发布。
Photo by Vidmir Rais via Pixabay
照片由 Vidmir Rais 通过 Pixabay 拍摄
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧